LC2s are defined by their ability to produce type 2 cytokines, in particular IL-5 and IL-13, by integrating inputs from multiple ligands, including cytokines, neuropeptides, and eicosanoids 1,2 . The epithelial cytokines IL-33, IL-25, and thymic stromal lymphopoietin (TSLP) are powerful ILC2 activating ligands, and mice deficient in these signaling pathways display substantial compromise in the capacity of mature lung ILC2s to generate type 2 cytokines in response to helminths and allergens [3] [4] [5] [6] [7] . Recent analyses of murine and human ILCs have indicated transcriptomic heterogeneity of ILC2s in tissues 8-10 ; however, direct comparisons of ILC2s among normal resting tissues are limited and complicated by sorting strategies that rely on surface markers that are variably expressed by ILCs. Furthermore, functional characterizations of the signals that establish the homeostatic activation profiles of ILC2s across and within disparate tissues, particularly in skin, are lacking.
the Yarg + bone marrow ILC2 population by their ability to produce hallmark ILC2 cytokines ( Fig. 1c-e ).
The widespread distribution of R5 + ILC2s in resting tissues suggested that ILC2s were activated by stimuli in the absence of apparent exogenous challenge. To decipher these signals, we performed RNA sequencing (RNA-seq) to compare the transcriptomes of purified R5 + ILC2s isolated from lung, gut, fat, and skin against Yarg + ILC2s from bone marrow (which are R5 -). Compared to bone marrow ILC2s, peripheral tissue steady-state ILC2s expressed increased transcripts encoding growth factors, cytokines and cytokine-related genes (for example, Areg, Il2, Il5, Il13, Lif, Tnf, Tnfsf10, and Cish), transcriptional regulators (for example, Fos, Jun, Klf4, Klf5, Klf6, Irf4, Maff, Egr1, Egr2, Epas1, and Nfkbiz), nuclear factors (for example, Nr4a1, Nr4a2, and Nr4a3), enzymes (for example, Tnfaip3, Plk3, Clk4, Dusp1, Dusp4, Dusp5, and Dusp10), and extracellular receptors associated with lymphoid cell activation (for example, Cd44, Cd69, Il2rb, Ctla4, Kit, Ccr4, and Ccr8; Fig. 1f, Supplementary Fig. 2 , and Supplementary Table 1 ). These results highlight the basal activation state of tissue-resident ILC2s, although heterogeneity was apparent among different tissues. Indeed, the transcriptional profile of steady-state tissue ILC2s resembled the shared transcriptional programs of tissue-effector ILC2s and CD4 + helper T cells (T H 2) cells elicited by type 2 immune stimulation 7, 17 .
Basal ILC2 activation is independent of microbiota. Steadystate stimulation by commensal microbes has been implicated in epigenetic and transcriptional alterations among intestinal ILC subsets 10 . With this in mind, we examined the tissue ILC2 activation program in germ-free mice as compared with mice housed in specific-pathogen-free (SPF) barrier conditions. Similar numbers of ILC2s (defined in lungs, skin, fat, and bone marrow as Lin -CD45 + Thy1.2 + CD25 + , or in gut as Lin -CD45 + KLRG1 + IL-17Rb + , in the absence of the fluorescent reporters) were recovered from the lungs, skin, gut, fat, and bone marrow of germ-free and SPF mice ( Fig. 2a-c and Supplementary Fig. 3a,b ). Additionally, steadystate eosinophil numbers, which depend on ILC2-derived IL-5 11 , were not significantly different in germ-free animals as compared to SPF controls (P = 0.0661; Fig. 2d ), indicating that although the presence or absence of particular commensal microbes can alter intestinal ILC subset composition 10 , these changes do not significantly impact cytokine-influenced functional outcomes of the tissue ILC2 activation program. In confirmation of these findings, we detected similar expression of Il5 transcripts in comparing germfree and SPF ILC2s isolated from bone marrow, fat, lung, gut, and skin ( Fig. 2e ). Transcriptional abundance for Gata3 and Arg1, and for receptor components for tissue-derived cytokines, such as Il1rl1 (encoding the IL-33 receptor subunit T1/ST2), Il17rb (encoding the IL-25 receptor subunit IL17RB), and Tnfaip3 (encoding the ubiquitin-modifying enzyme A20 induced by nuclear factor kappalight-chain-enhancer of activated B cells (NF-κ B) signaling), were also comparable ( Supplementary Fig. 3c -g). Thus, tissue programs driving peripheral ILC2 activation are independent of commensal microbes and are likely driven by tissue-intrinsic signals.
Distinct tissue signals drive resident ILC2 activation. Tissuederived signals, such as the cytokines IL-25, IL-33, and TSLP, control type 2 cytokine production from ILC2s in peripheral tissues in response to infectious or homeostatic perturbations 3, 7, 15, 18, 19 , and they synergize with other ILC2 activation signals such as leukotrienes 20 and neuropeptides 21 . We assessed whether these three signals contributed to the resting activation profile of ILC2s by examining multiple tissues from triple-reporter YRS and TKO-YRS mice, which lack responsiveness to TLSP, IL-33, and IL-25 cytokine signals. Notably, TKO-YRS mice harbored normal numbers of total ILC2s in lung, fat, and gut (lung, P = 0.1024; fat, P = 0.6638; gut, P = 0.0636; Fig. 3a -c), although the numbers of activated IL-5expressing R5 + ILC2s were significantly reduced in these peripheral tissues (lung P = 1.6244 × 10 -7 ; fat, P = 0.0009; gut, P = 6.0366 × 10 -18 ;
Fig. 3d-f and Supplementary Fig. 4 ), extending prior observations of lung ILC2s 7 . Peripheral eosinophil numbers were also diminished in TKO-YRS mice, consistent with the role for ILC2s in sustaining systemic IL-5 ( Fig. 3g ). The magnitude of the reduction in R5 + ILC2s, however, was not consistent among peripheral tissues; notably, the skin contained comparable numbers of R5 + ILC2s in wild-type YRS and in TKO-YRS mice ( Fig. 3h ), indicating that signals other than IL-25, IL-33, and TSLP sustain steady-state IL-5 production from skin ILC2s. To explore this further, we compared the transcriptional profiles of ILC2s from YRS and TKO-YRS mice isolated from multiple tissues. In agreement with the reporter gene expression and in agreement with prior studies 7, 15, 19 , type 2 cytokine transcripts were reduced in TKO-YRS ILC2s isolated from lung, fat, and gut ( Supplementary  Fig. 5d,e ). Clustering based on the top 1,000 differentially expressed genes, however, revealed that the major transcriptional signatures *** from wild-type and TKO ILC2s were tissue-specific and independent of the presence or absence of these epithelial cytokines ( Fig. 4a and Supplementary Fig. 5a Il18r1 expression in skin ILC2s ( Fig. 4b , Supplementary Fig. 5f ,g, and Supplementary Table 1 ). Collectively, these findings suggest that distinct tissue-derived factors contribute to ILC2 subset activation in the steady state.
Single-cell RNA-sequencing distinguishes ILC2 subsets. To explore further the nature of ILC2 tissue signatures and to discern whether these differences identified by bulk RNA-seq resulted from contamination by nonhematopoietic tissue cells, we performed single-cell RNA-sequencing (scRNA-seq) on 35,396 sorted ILC2s from bone marrow and peripheral tissues. In confirmation of the bulk sequencing results, scRNA-seq analysis of the aggregated ILC2s from multiple tissues showed segregation by tissue, which could be further subclustered within each tissue, revealing novel intratissue ILC2 subsets ( Fig. 5a and Supplementary Fig. 6a-c) . We observed minimal ( < 2%; Supplementary Fig. 6b ) contamination by non-ILC2 cells, and, in agreement with the bulk sequencing results, common transcripts such as Gata3, Il7r, and Crlf2 (encoding the TSLP receptor subunit TSLPR) were expressed by the majority of ILC2s across tissues, whereas other transcripts were enriched in particular tissues (Fig. 5b-f and Supplementary Figs. 6c and 7) , consistent with tissue-specific functional roles. Il1rl1, encoding an IL-33 receptor subunit, was enriched among fat and lung ILC2s, corresponding to a loss of IL-5 reporter R5 expression in ILC2s from these tissues in mice lacking this receptor ( Fig. 5d and Supplementary Fig. 4 ). The gene encoding IL-25R, Il17rb, was abundant among gut ILC2s and matched the loss of R5 expression predominantly seen among smallintestinal ILC2s in mice lacking IL-25 ( Fig. 5e and Supplementary   Fig. 4 ). These findings are consistent with prior studies linking IL-33 to steady-state ILC2 function in fat and lung 19, 22 and IL-25 to small-intestinal ILC2 function 15, 23 . In contrast, skin ILC2s showed comparatively low expression of both IL-25 and IL-33 receptors, as assessed both by flow cytometry and transcript analysis, and consistent with unaltered IL-5 expression among TKO skin ILC2s (Fig.  5d ,e,g, Supplementary Figs. 4 and 6c , and Supplementary Table 1 ). Of note, skin ILC2s expressed IL-18R1 (CD218) cell surface protein and Il18r1 transcripts, even in germ-free mice ( Supplementary  Fig. 3h ). In agreement with the bulk RNA-seq results, IL-18 receptor subunit expression was also enriched in subsets of lung and bone marrow ILC2s identified by scRNA-seq and flow cytometry (Fig. 5f,h and Supplementary Fig. 6b,c) . These findings raise the possibility that IL-18 could influence ILC2 function in a tissue-and subset-specific manner.
IL-18 independently activates IL-18 receptor-bearing ILC2s.
IL-1 cytokine family members, including IL-18 and IL-33, can induce cytokine expression from lymphoid cells, particularly in the presence of STAT5 activators such as IL-7 and TSLP 24, 25 . To test the function of IL-18 on these IL-18R-bearing peripheral ILC2 subsets, we sorted ILC2s from skin and lung and cultured them with IL-18 and TSLP in vitro. Compared to TSLP alone, ILC2s produced significantly higher amounts of IL-13 in the presence of IL-18 (skin, P = 0.0066; lung P = 0.0021; Fig. 6a ), in agreement with a recent characterization of IL-18-responsive ILCs isolated from human tissues 9 . Intradermal injection of IL-18 and TSLP into S13 reporter mice increased IL-13 reporter expression among both skin and lung ILC2s (Fig. 6b) , indicating that IL-18R1 expression on ILC2s mediates type 2 cytokine production from these cells in response to IL-18. To determine whether IL-18 contributes to the steady-state production of type 2 cytokines from ILC2s, we compared Smart13 and R5 reporter allele expression on wild-type ILC2s to those on an IL-18-deficient background (IL-18 knockout). Although the numbers of R5 + ILC2s in wild-type and IL-18 knockout mice were comparable ( Supplementary Fig. 8a,b) , Smart13 expression and R5 fluorescence were significantly reduced in IL-18-deficient skin ILC2s in comparison with wild-type control cells (Smart13, P = 0.000472; R5. P = 0.00570; Fig. 6c,d) , revealing a nonredundant role for IL-18 as a steady-state activator of IL-18R1-expressing ILC2s. We considered how IL-18 might contribute to steady-state activation of ILC2s in the presence or absence of other endogenous activating cytokines, including IL-25 and IL-33, in light of their tissue-and subset-specific receptor expression patterns. Although total R5 + ILC2s were reduced in the lungs of TKO animals ( Fig. 3d and Supplementary Fig. 4) , the IL-18R1 + R5 + ILC2 subset was expanded in number when compared to wild-type control mice, both in the steady-state and in response to intranasal IL-18 (Fig. 6e) . These observations indicate that IL-18 could preferentially mediate activation and type 2 cytokine production from the IL-18R1expressing ILC2 subset independent of IL-25, IL-33, and TSLP. In further support of this notion, IL-18 mediated activation and cytokine reporter expression among bone marrow IL-18R1 + Yarg + ILC2s in the absence of IL-33R (ST2) expression, although the latter was required to respond to IL-33 (Fig. 6f ). As receptor components for both IL-33 and IL-18 were expressed on some ILC2 subsets, we tested whether these two cytokines combined to control the steadystate expression of IL-5 in IL-18R1-expressing ILC2 subsets in skin and lung. Indeed, R5 expression among lung and skin ILC2 subsets bearing CD218 and/or ST2 was substantially reduced in mice that lacked both IL-18 and the IL-33 receptor ST2 when compared to wild-type controls (Fig. 6g) . Thus, patterns of activating receptors have biologic significance that are organ-specific and based upon the subsets of ILC2s populating that tissue.
Blunted type 2 skin inflammation in the absence of IL-18. ILC2s have been shown to be increased in lesional skin of patients with atopic dermatitis and in mouse models of atopic dermatitis-like inflammation 5, 26 . Our findings that IL-18 activated skin ILC2s and that loss of IL-18 led to reduced activation of skin ILC2s in homeostasis ( Fig. 6a-d ) led us to further examine whether IL-18 contributed to ILC2 function in the context of an in vivo mouse model of skin inflammation. To test this, we used topical application of MC903, a well-characterized mouse model of atopic-like inflammation that has been shown to activate ILC2s and cause eosinophilia, skin swelling, and type 2 inflammation 26 . Compared to wild-type mice, IL-18-deficient mice exhibited decreased skin tissue accumulation of total ILC2s and of IL-5-and IL-13-producing ILC2s (Fig. 7a-c) , which are critical determinants of eosinophil recruitment into tissues 7 . Indeed, mice deficient in IL-18 also showed a corresponding decrease in the numbers of eosinophils recruited to ear skin tissue in response to MC903 (Fig. 7d) . These data suggest that IL-18 not only influences basal ILC2 subset activation in the steady-state but also contributes to its function in models of atopic dermatitis.
Discussion
ILC2s are largely tissue-resident cells with a canonical effector function centered on the production of type 2 cytokines, particularly in response to key activating cytokines like IL-33, IL-25, and TSLP. Here we show that expression of these cytokine receptors impacts cytokine discharge from ILC2s, but with varying effects in different tissues, reflecting diversity in receptor expression on ILC2 subsets in different organs. Indeed, some ILC2 subsets, including most skin ILC2s, express low levels of receptors for epithelial cytokines IL-33, IL-25, and TSLP; instead they are activated dominantly by IL-18, which is highly expressed in skin ILC2s and in subpopulations of ILC2s in lung and bone marrow. Strikingly, transcriptomic profiling of ILC2s revealed tissue-specific subsets of cells whose expression patterns remained largely unaffected by the absence of signaling through the three canonical epithelial cytokines. These tissuespecific expression patterns, including the capacity to respond to epithelial cytokines or IL-18, were normal in germ-free and cytokine-deficient mice, uncovering a tissue-derived signature responsible for preemptively establishing responsiveness of ILC2 subsets in different tissues in an anticipatory fashion, since normal receptor expression and tissue distribution occurred even in the absence of ligand-mediated stimulation.
These tissue signatures reveal new potential therapeutic targets among particular cytokine receptor-bearing subsets of ILC2s. Notably, in IL-18-deficient mice, the IL-18R-bearing ILC2s in the skin exhibited a substantial defect in the homeostatic activation of ILC2s in vivo. Moreover, ILC2 proliferation and activation, as well as eosinophil recruitment, were blunted in IL-18-deficient animals after skin challenge with MC903, a well-characterized mouse model of atopic-like dermatitis. These results are particularly noteworthy, as transgenic mice that overexpress IL-18 in keratinocytes develop severe dermatitis 27 , and elevated IL-18 correlates with disease severity in atopic dermatitis 28, 29 , raising the possibility that targeting IL-18 may represent a means to ameliorate type 2 immune activation in the skin. In addition, given that receptor components for both IL-33 and IL-18 were expressed on some ILC2 subsets, activation by these two signals either alone or in combination may influence allergic diseases like asthma and atopic dermatitis. Indeed, the genes for IL-18R1 and IL-33R receptors are located together in the genome at an interval linked by genome-wide association studies with risk for allergic diseases in large cohorts 30, 31 .
Further study using appropriate fate-mapping tools will be required to determine whether these tissue-specific expression profiles are acquired during fetal or perinatal development when ILC2s become established in tissues 12, 16, 32 , and how these programs are engaged during differentiation from bone marrow precursors in adults, or after tissue insults like helminths and allergens. Strikingly, ILC2 effector function is expressed postbirth and may create an additional layer of control along with tissue-resident macrophages during this critical period of growth and development, in which cell identity becomes established in temporal proximity to tissue differentiation 33 , and before the maturation of tissue-resident adaptive immunity. Notably, our findings suggest discrete stages in the development of mature tissue ILC2s 34 . ILC2 precursors are first seeded into tissues, where they acquire a tissue-specific transcriptome characterized by expression of distinct subsets of activating receptors and an activated, poised phenotype. The subsequent generation of the canonical type 2 cytokines is then regulated by the generation of distinct sets of ligands that converge on receptors expressed by ILC2s specific to that tissue. How and why these diverse tissue pathways converge on the canonical type 2 cytokines and related effectors in ILC2s distributed across multiple tissues continues to be an important issue that may provide understanding of processes firmly at the nexus of homeostasis and allergic immunity. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
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